Puma Bio stock: buy or sell?
October 18th, 2019
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care.
Should I buy Puma Bio stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Following a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Puma Bio stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Puma Bio stock a buy?
Banks and financial institutions post stock ratings everyday.At Stocks2.com, we collected 12 ratings published for PBYI stock in the last month. The general sentiment of these ratings is bearish for PBYI stock, with 4 negative ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-12||JPMorgan Chase & Co.||n/a||Sell|
|2019-5-29||Goldman Sachs Group||n/a||Neutral|
|2019-5-10||JPMorgan Chase & Co.||n/a||Underweight|
|2019-1-17||Leerink Swann||n/a||Market Perform|
Puma Bio stock analysis
Shares of Puma Biotechnology eased a shocking -2.69% and closed at $6.50.
Puma Biotechnology eased a shocking -2.69% and closed at $6.50. For the last 19 days when PBYI stock price broke down the SMA50d line, it slid $-4.27 per share (-39.65%).
Puma Biotechnology shares plummed -8.84% this week, ending at $6.50. This was the third red week in a row, sliding in full a -43.07%.
Once Puma Bio failed to resist above the support, it inescapably dropped deeper. Since price and 40-weeks moving average lines crossed down early April, PBYI fell $-28.96 per share (-81.67%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support.
Puma Bio stock price history
Puma Bio stock went public on April 24th, 2012 with a price of $13.001. Since then, PBYI stock sliced a -50.00%, with a yearly average of -7.10%.
1: Adjusted price after possible price splits or reverse-splits.
Puma Bio stock historical price chart
PBYI stock reached 52-week highs at $45.90, and all-time highs 2014-08-26 with a price of 279.37.
Puma Bio stock price target is $29.40Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' PBYI stock price predictions in the hope that they will be met as they may be wrong and not met. We found 9 price predictions for Puma Biotechnology stock released in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-12||JPMorgan Chase & Co.||Reiterates||n/a||$13.00||-|
|2019-5-29||Goldman Sachs Group||Lowers Target||$29.00||$24.00||-17.2%|
|2019-5-10||JPMorgan Chase & Co.||Lowers Target||$27.00||$19.00||-29.6%|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Puma Bio failed to meet the expectations of the experts and reported a tragic EPS of $-0.80 per share when experts were expecting $-0.92.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw a super good increase of 806.60% to $250.99 M dollars. Similarly, its profit margin (compared to sales) skyrocketed to -45.25%, that is $-113.58 million.
|2017||$28 M||-||$-291.96 M-1054.6%||-|
|2018||$251 M||806.60%||$-113.58 M-45.3%||-61.10%|
Quarterly financial resultsPuma Bio posted $71.08 M in sales for 2018-Q4, a 13.49% improvement compared to previous quarter. Reported quarter earnings marked $-30.70 million with a profit margin of -43.18%. Profit margin plunged a -20.51% compared to previous quarter when profit margin was -22.67%. When comparing sales to same quarter last year, Puma Biotechnology sales marked an astounding gain and rocketed a 228.95%. Looking back to recent quarterly results, Puma Bio posted 2 positive quarters in a row.
|2017-Q3||$6 M||-||$-77.18 M-1269.4%||-|
|2017-Q4||$22 M||255.39%||$-64.08 M-296.5%||-16.98%|
|2018-Q1||$67 M||207.83%||$-24.35 M-36.6%||-62.01%|
|2018-Q2||$51 M||-23.68%||$-44.34 M-87.3%||82.11%|
|2018-Q3||$63 M||23.37%||$-14.20 M-22.7%||-67.97%|
|2018-Q4||$71 M||13.49%||$-30.70 M-43.2%||116.15%|
Puma Bio ownershipWhen you are planning to invest in a stock, it's worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Puma Bio, 13.44% of all outstanding shares are owned by its staff.
Bearish positions for PBYI stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$252.9 M||$13.5 M||$105.9 B||$201.6 B|
|Total shares||38.9 M||16.7 M||2,490.0 M||5,530.0 M|
|Float shares||30.9 M||13.9 M||2,450.0 M||5,520.0 M|
|- Institutional holdings (%)||100.9%||8.1%||11.0%||76.2%|
|- Insider holdings (%)||13.4%||16.9%||0.0%||0.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%|
Puma Bio summary
|Friday, October 18th, 2019|
|Day range||$6.48 - $6.71|
|Average true range||$0.63|
|50d mov avg||$10.21|
|100d mov avg||$11.07|
|200d mov avg||$20.38|
Puma Bio performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. In the following table, we compare Puma Bio performance to Dare Bioscience, GlaxoSmithKline and Pfizer: